PathXchange, the Preferred Online Pathology Community, Surpasses 12,000 Members

Rapid growth of PathXchange signals mainstream adoption of digital pathology tools by pathologists

TUCSON, Ariz., March 1, 2011 /PRNewswire/ -- PathXchange.org, a global online pathology website, today announced that they have exceeded 12,000 registered members from over 160 countries. PathXchange services are the most widely used professional networking, collaboration and e-learning tools enabled by digital pathology.  

Since its launch in June 2009, PathXchange has experienced unprecedented growth.  Pathology professionals from clinical, research, and educational institutions widely utilize PathXchange for an increasing array of use cases including tumor boards, peer consultations, case conferencing, research studies, residency training, and continuing medical education (CME).

Dr. Mahul B. Amin, Chairman and Professor, Dept of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, an active supporter of PathXchange services since its launch in June 2009, noted the power and global reach of this Web 2.0 tool. He commented, "PathXchange was instrumental in allowing us to read a second opinion case with less than 24-hour turnaround time, with the ability for pathologists in India and California to simultaneously review case slides."

PathXchange.org is available to individual users free of charge.  Dedicated and secure microsites are available at a reasonable fee to institutions seeking to leverage PathXchange networking technologies for their own pathology applications.

About PathXchange

PathXchange services brings the field of pathology into the digital age with Web 2.0 features designed to promote the exchange of pathological cases, ideas, knowledge, information, products, and services. PathXchange.org website (excluding linked sites) is controlled by Ventana Medical Systems, Inc. within the State of Arizona, United States of America. It can be accessed throughout the United States, as well as from other countries around the world.

2011 Executive War College Registration Open

Learn more now!

In these challenging times, you'll hear all the experts, all the topics, and find all the resources you need for your laboratory to acquire the competitive edge! Don't miss thie annual event. Is your lab prepared for the disruptive trends and swift changes to our healthcare system?

1. Challenging Economic Trends Continue
2. Healthcare Reform
3. Disruptive Molecular Trends
4. New Technologies

More than 50 key not speakers confirmed so far, many more to be posted... see the speaker lineup!

If you missed the 2010 Executive War College or if you want to share what your heard in New Orleans.
Order Audio Recordings NOW!

The Paula Takacs Foundation for Sarcoma Research

Ask anyone who has worked in healthcare as a provider of care or technology or related services and they will no doubt have a story or two about a particular patient to recall and how it changed their lives.  These patients and their stories allow us to remember why we went into our chosen profession and what it means to be a healthcare provider or provide goods or services in the healthcare industry. 

I still recall encouters with patients and their names from the time I worked as an orderly during college.  The stories have accumulated through medical school and residency. Additional stories are added on a regular basis from discussions at multidisciplinary conferences and tumor boards. All are inspiring. 

I recently became aware of someone in my community, Paula Takacs, who is a cancer survivor and has recently started a foundation for sarcoma research.  After battling her disease privately with close friends and family, she and her family have shown incredible strength in taking Paula's message public to spread the word and raise research funding. 

You can learn more about Paula's story on her website

On April 2nd, the first annual fundraiser for The Paula Takacs Foundation will be The Sarcoma Stomp 5K/ Fun Walk in Charlotte. Proceeds of this fundraiser will benefit the Kristen Ann Carr Sarcoma Laboratory at Memorial Sloan-Kettering Cancer Center (MSKCC) in New York. 

More about Paula and her incredible strength.

 

 

Be There Anywhere (TM) HD TelePathology

top500.jpg

Now clinicians can receive real-time high definition video through ordinary internet connections and without the need for special software.

Forget about the limitations and cost burdens associated with conventional telepathology systems.Traditional products typically include special hardware at each end, limit users to specific point-to-point communication processing, and require client software downloads. Be There Anywhere™ eliminates these complexities, requiring only the compact iMedHD™ package and Internet connectivity. This highly secure offering, with video capture capabilities, is the ideal solution for real time Internet sharing and collaboration of true live high definition images.

  • Enables medical clinicians to use live 1080p HD imaging.
  • All that is needed is any PC or MAC web browser and a broadband Internet connection.
  • No need for special hardware or software.
  • Incredibly intuitive and easy to use, even for first-time users – no user manual is necessary.
  • Multiple clinicians can easily communicate – all participants have shared pointing and annotation abilities.
  • Optional webcam, Voice over IP, document presentation and desktop sharing capabilities.
  • Dynamic browser control for an excellent live HD viewing experience – all can easily adjust image display.
  • Allows immediate informed diagnoses and decision-making when time is of the essence.
  • With RMT’s new phone-home capability the solution can be easily moved to any location for flexible use and provides significant cost benefits.

For more information, or an online demonstration, call Don Marchon at
1-888 988-8439 • don.marchon@rmtcentral.comhttp://www.rmtcentral.com

logos.png

 

USCAP and Aperio Launch Digital Archive of the Juan Rosai Collection of Surgical Pathology Seminars

Partnership Provides Free Digital Archive Showcasing the Contribution of Surgical Pathology to Patient Care Dating Back to 1945

Augusta, GA and Vista, CA – February 22, 2011 - The United States and Canadian Academy of Pathology (USCAP), the global leader in the transmission of knowledge in the field of pathology for more than a century, and Aperio, the global leader in providing digital pathology solutions that improve patient care, will be showcasing the digital launch of the Dr. Juan Rosai Collection of Surgical Pathology Seminars at the 100th USCAP Annual Meeting, to be held February 26 – March 4, 2011, at the Henry B. Gonzalez Convention Center, San Antonio, TX. (Booth 114 has been reserved for viewing of the collection.) 

Dr. Juan Rosai, a world-renowned expert and consultant in surgical pathology, has donated his extensive glass slide seminar series collection inherited from the late Lauren V. Ackerman, MD for the world to view. The complete collection consists of almost 20,000 cases originally presented at more than 1,400 pathology seminars, and comprises digital slide images of the original slides, clinical history, and diagnostic summaries, along with present day commentary by Rosai and other experts. At this time, seminars are continuously being added to the site, with the full collection to be accessible within the coming months. 

“I am honored that the USCAP and Aperio have collaborated to provide the pathology community with a digital archive and interactive learning environment for this one-of-a-kind, historical collection,” said Rosai. “Now, pathologists around the world will be able to access and learn about the evolution of patient care from a pathology perspective. I am very appreciative that the collection will be preserved for eternity for the future of pathologists around the world.” 

USCAP and Aperio announced their partnership in 2010 to develop the infrastructure for a digital archive. The collection has been digitized using Aperio’s ScanScope® scanners to ensure high-resolution image quality, and is accessible to the global pathology community, free of charge, through the USCAP website (http://www.USCAP.org). The USCAP has developed a custom-built website to dynamically interact and interface with the digital slide collection to provide diagnostic and historical context, as well as interactive learning tools. The whole-slide images are hosted by SecondSlide®, Aperio’s free, secure, digital slide sharing service for pathology. 

Victor Reuter, former president of the USCAP and vice chair of the Department of Pathology at Memorial Sloan-Kettering Cancer Center, commented, “Dr. Rosai has served as an inspiration to thousands of pathologists throughout the world for many decades. He epitomizes everything that morphology has contributed to the understanding of disease across many disciplines. A masterful teacher, it should not surprise us that he has maintained this collection over the years and has now chosen to share it with the global pathology community. I congratulate Aperio and USCAP for supporting this project that is sure to have profound educational and historical importance.” 

“Aperio’s ongoing advancements in digital pathology systems, including our patented, high-resolution slide creation, image visualization techniques and innovative slide sharing systems are completely transforming the pathology landscape,” stated Jared N. Schwartz, MD, PhD, chief medical officer at Aperio. “Digital pathology provides the means to significantly advance scientific knowledge, whether it be through the preservation of valuable slide archives like the Juan Rosai collection, identifying biomarkers to advance personalized medicine, or connecting two pathologists in different parts of the world for pathology consultation.”

About USCAP

The United States & Canadian Academy of Pathology (USCAP/IAP) has been the global leader in the transmission of knowledge in the field of pathology for more than 100 years. The Academy has had a rich heritage of leading the provision of highest standards of pathology education for pathologist members like no other organization and attracts to its ranks the leaders in key areas of pathology. 

The phrase "Leading Pathology Educational Excellence," used in conjunction with the USCAP graphic identity, provides an accurate and appropriate description of the Academy's activities on two levels: 1) providing "leading pathology educational excellence" via its faculty and programs; 2) leading "pathology educational excellence" with ongoing innovation and scientific breakthroughs for the field of pathology. 

Through the efforts of its outstanding membership, the USCAP is able to extend educational excellence to Pathologists around the world.  

 

About Aperio

Aperio is the leading provider of digital pathology solutions in hospitals, reference labs, and pharmaceutical and research institutions across the world. Today, our affordable and complete product portfolio improves patient care by enhancing quality assurance, delivering more efficient workflows, facilitating access to new and more targeted therapies, and improving pathologists’ skills via lifelong education. Our comprehensive product line features our ScanScope® scanners, Spectrum™ image management (PACS) software, SecondSlide® slide sharing service for pathology, and image analysis tools and services. Aperio’s products are FDA cleared for specific clinical applications, and are intended for research and education use for other applications. For clearance updates and more information please visit http://www.aperio.com.   

 

New app will give docs access to records ‘anytime, anywhere’

Doctors soon will be able to look at medical records whenever and wherever they need to--and email or video chat with other doctors about those records--thanks to a mobile application created by Southern California-based innovation leader Palomar Pomerado Health being unveiled this week at HIMSS11 in Orlando.

The app, known as Medical Information Anytime Anywhere (MIAA), gives docs the ability to view records from any number of providers without having to worry about the compatibility of different software systems used, reports the San Diego Union-Tribune. MIAA breaks down records into a common format, according to the newspaper.

Dr. Orlando Portale, chief innovation officer for PPH, and his team have taken data from four different sources and served it up into a view that runs on an Android operating system, Kathy English, director of healthcare product solutions for Cisco, told FierceMobileHealthcare. The system, according to a PPH announcement, is interoperable with electronic health record systems such as Cerner Millennium, NextGen and the Veterans Administration (VistA) system.

"Everybody wants to do this," Ed Babakanian, University of California San Diego Health System information officer, told the Union-Tribune. "I think the novel element is the extent to which it can integrate information from a number of sources."

Cisco fronted half the prototype development money for the application, which is being designed in tandem with a new $1 billion hospital set to go up in the area. A pilot program for the app in which Escondido-based Palomar Medical Center West will work with Poway-based Arch Health Partners, will start in September, the newspaper reports.

"It's raw," Cisco's English said. "It's real, but it's raw."

To learn more:
- read this San Diego Union-Tribune article
- check out this Palomar Pomerado Health press release

Related Articles:
Smartphone boom changes physicians' relationship with technology

New apps make smartphones more valuable than stethoscopes to some docs
Sutter app gives patients access to records on the go
Physician smartphone adoption said to top 80 percent by 2012

Courtesy of Dan Bowman Fierce Mobile Healthcare

Is it really possible to scan a slide under 60 seconds at 40x?

dig-path.jpg

To find out, visit Philips Digital Pathology at the USCAP 2011
Booth #801, February 28 - March 2, SanAntonio, TX (USA)

digital-pathology.jpgWhen it comes to digital pathology, performance is defined by speed and image quality. That’s why Philips has developed a faster, total solution. The Digital Pathology Solution* includes an ultrafast scanner and integrated image management system with exceptional scan times of less than 60 seconds at 40X,simplifying workflow for better efficiency and collaboration.

You are invited to learn more about our total solution at the Philips booth #801 at the USCAP February 28th - March 2nd.

Visit our website for further information: http://www.philips.com/digitalpathology

 

2nd Generation Brightfield versus 1st Generation Fluorescence Scanners

This post is submitted by Steve Potts, CEO of Flagship Biosciences, a companion diagnostics company. 

“A truly great book should be read in youth, again in maturity and once more in old age, as a fine building should be seen by morning light, at noon and by moonlight.” -- Robertson Davies

These are exciting times to be consumers of digital pathology hardware. We are at the end of the 2nd generation brightfield scanners (1st Generation were the automated microscopes of CAS / VIAS / ACIS, and 2nd generation are the Nanozoomers / ScanScopes / Mirax scanners with great 20x whole slide scanning performance). Our in-house definition of a 3rd Generation brightfield scanner is the speed, quality, and error rates we expect from 2nd Generation scanners at 20x, but performed at 40x. This represents a four-fold improvement (20x to 40x is four times longer) in the last three or four years --Moore’s law marches on in brightfield scanning. To evaluate a 3rd Generation scanner, take a set of five slides to USCAP or other pathology show, and with a stopwatch evaluate the time, quality and error rate of the scans at 40x among the various new products. We are just beginning 3rd generation devices, and there are a lot of new and existing companies with innovative offerings in 2011. USCAP and CAP will likely demonstrate some fabulous choices for scanner consumers!

Now let’s look at fluorescence. At January’s Applied Immunohistochemistry and Molecular Pathology Retreat in Miami (IMHO the best and most serious conference on practical IHC year after year) there was an interesting comment, “Fluorescence microscopy is far ahead of brightfield microscopy in quantitation, but fluorescence scanning is far behind brightfield scanning”. Fluorescence scanning is simply a LOT harder than brightfield scanning. The four major fluorescent scanners on the market (3DHistech Pannoramic, Olympus VS110, Hamamatsu Nanozoomer, and the Aperio ScanScope FL) all have different advantages, and this blog could go on for pages discussing specific design tradeoffs we've evaluated. We run both brightfield and fluorescent scanning in high volume in our digital pathology lab, and here are some differences between the two scanning modalities that users should be aware of, regardless of which system is chosen:

Scanning Time:

  • BRIGHTFIELD: For 15mm x 15 mm tissue sections, expect brightfield scanning times of 3 minutes at 20x, and 8-10 minutes at 40x.
  • FLUORESCENCE: For fluorescence (our normal operation is three or four colors), expect 2-3 slides per hour at 20x. Forget about 40x fluorescence on whole slide images. 

QA and failure rate:

  • BRIGHTFIELD: Expect to spend at least 1 minute per slide for a technician to QA a brightfield slide manually, this is required for good brightfield scanning operations, and far too many people don’t do this. Failure rates of 5% for 20x and 20% for 40x are normal, but these numbers are largely dependent on histology and slide preparation.
  • FLUORESCENCE: Expect rescan rates of 20-40% at 20x, this is very much dependent on the given sample and the skill of the operator and how well tuned the fluorescent scanner is. The errors will come primarily from the tissue sample more than from the fluorescent scanning. Things like debris on the cover slip, Rocky Mountain-like tissue samples, dye over stains, are not as problematic for a brightfield scan as a fluorescent scan. 

 

Technician Skill:

  • BRIGHTFIELD: Brightfield scanning requires a very methodical person, who is consistent and pays attention to detail in QA of each slide. There is very little biology discussion required, and scanning settings are not changed that much between studies. In other words, the scanning is generally the same regardless of histology, for most projects (TMA scanning and Z-stack do require specialized settings).
  • FLUORESCENCE:  Every study requires specific knowledge of the biology that then must be used in deciding on scanning settings. One has to know the amount of autofluorescence, the differences between autofluorescence and signal in the tissue, the goal of the study. If quantitation of protein expression is required, a number of steps need to be in place standardizing the scan times and comparisons to controls, and control preparation. In short, the scanning settings are entirely dependent on the biology of each study. In our lab, a skilled Master’ level biologist runs the scanning, and we get the best results when he knows (before the study) the biological endpoint the client is trying to achieve. 

Fluorescence whole slide scanning technology is improving, and offers powerful multiplexing applications, but everything mentioned previously helps explain why there are 16 FDA protein expression clearances in brightfield digital imaging, and none in fluorescence. The pathologist's adoption of fluorescent scanning is another factor.

Apollo to Showcase Enterprise Patient Media Manager in the “Cloud” at HIMSS 2011

Falls Church, VA – February 18, 2011 - Apollo PACS, Inc., (Apollo), a provider of clinical multimedia solutions, is launching its proven Apollo Enterprise Patient Media Manager (Apollo EPMM®) solution in the “Cloud.”  Apollo will be showcasing their latest service offering for healthcare providers and IT professionals at the Annual HIMSS Conference & Exhibition at Booth #462 in Orlando, Feb. 21-23, 2011. As a multi-tiered, open-system software solution, Apollo EPMM® helps healthcare institutions improve patient care and operational efficiency by providing specialty-specific workflow enabling simple and secure access to clinical multimedia content.

This cloud-based model enables healthcare organizations of all sizes, as well as individual physicians and allied health professionals, to secure, manage and access clinical multimedia content from their desktop at a low subscription fee that includes full use of the application and all necessary storage. This “pay-as-you-go” model removes the up-front capital expenditures and IT infrastructure typical of large scale information technology purchases and makes Apollo EPMM® an operational budgetary item for its customers. This enables customers to increase storage capacity on the fly without investing in new infrastructure, personnel, or software.

"Easy-to-use workflow and access to clinical multimedia content improves patient care, providing clinicians with visual and/or aural information about a patient and his or her medical history over time. Except for radiology imaging, clinical multimedia is virtually inaccessible and unsecure," said Mark Newburger, CEO of Apollo. "Apollo EPMM® integrates with a multitude of capture devices and information systems to create a single, unified patient multimedia record that is easily accessible, secure, compliant and centrally managed. We are excited to have the opportunity to demonstrate this user-friendly application at HIMSS 2011."

By linking legacy systems across multiple departments and specialties, Apollo EPMM® is capable of locating, managing, and delivering clinical multimedia content to any user or group within the enterprise whether this information is originally stored in silos or a central data store.  Apollo EPMM® unifies and organizes the information and clinical workflow in a manner that is relevant to each specialty within the healthcare enterprise. Apollo currently provides over 40 specialty-specific solutions including Pathology, Dermatology, Gastroenterology, Ophthalmology, Plastic Surgery, and Pediatrics, among others.   Additionally, Apollo EPMM® includes a comprehensive rules-based security and audit trail, further ensuring patient safety and regulatory compliance.

An evolutionary step past traditional Radiology PACS, Apollo EPMM® is an interoperable solution that optimizes existing resources throughout the healthcare enterprise. Apollo EPMM® unifies all patient media without disruption, thereby transforming previously inaccessible multimedia files into a cohesive clinical information solution. The Apollo solution was developed in partnership with The Hospital for Sick Children, Canada's most research-intensive hospital and one of the world's largest and most respected pediatric academic health sciences centers.

Additional benefits of Apollo EPMM® include:
Easy, uniform multimedia access and management
Integrates and links multimedia with wide range of hospital solutions, including information systems and electronic medical records
Ability to capture, manage and archive existing and future multimedia file types
Device-agnostic, open-system approach that enables institutions to leverage legacy resources and adapt to future software and hardware changes
Adaptable to clinician workflows, department-to-department, institution-to-institution

About Apollo
Apollo is a trusted developer of clinical multimedia solutions that boost provider efficiency and improve care by enabling simple and secure management of, and access to, distributed clinical multimedia and data.

Apollo's open-system solutions optimize clinician workflow and efficiency, enabling institutions to make the most of legacy systems and turning multimedia into a unified clinical information solution.  Apollo solutions are assisting clinicians in the delivery of quality healthcare services to patients at leading academic centers, regional medical networks, commercial laboratories, and community hospitals throughout the US and Canada.  For more information visit: http://www.apollopacs.com. Follow us on Twitter and visit us in Booth #462 at HIMSS 2011.

Parade of Hopefuls in Digital Pathology

From CAP Today by Karen Lusky:

You know a new technology is catching on when the talk becomes less about whether it will be adopted and more about how and why. That shift appears to be taking place in the digital pathology world where the focus today is on how to make digital work for pathologists and laboratories. The digital pathology market itself is changing, too, as more vendors surface with different business agendas and strategies.

Read full story entitled "Parade of Hopefuls in Digital Pathology" in CAP Today.

Yours truly has a few quotes with my thoughts in the article and some counterpoints from others.

 

 

CBLPath Exhibiting at USCAP 2011 Annual Meeting, Booth #202

Best Practice™ Seminar Slated for Tuesday, March 1, at Noon

CBLPath will highlight its Best Practice™ Partnership Program at the upcoming United States & Canadian Academy of Pathology (USCAP) annual meeting February 26–March 4 in San Antonio, Texas. Attendees can visit Booth #202 in the exhibit hall to learn more about leveraging the convergence of anatomic, molecular and digital pathology to remain independent — Keeping Medicine Local™.

CBLPath will provide valuable information about the company’s full range of business and technology solutions that enable pathology Practices to deliver better medicine, faster. In addition to meeting company representatives USCAP attendees can:

  • Attend CBLPath’s Best Practice seminar on Tuesday, March 1, at 12 p.m.
  • Speak with Best Practice Program Partners
  • See a demo of LabIS®, CBLPath’s proven pathology management system

Attendees wishing to register for the seminar can do so online at http://www.CBLPath.com/BestPractice.

 

About CBLPath

CBLPath is a national specialty lab with a unique leadership position in the convergence of anatomic, molecular and digital pathology. Beginning from a clinical perspective, we harness molecular testing and digital pathology on an anatomic pathology foundation. CBLPath is committed to helping our clients deliver better medicine, faster. At our core are pathologists; excited about technology and innovation and its promise of helping patients. Through the Best PracticeTM Partnership Program we help our pathologist-clients effectively compete against centralized reference laboratories, grow their Practice and remain independent — Keeping Medicine Local™. We provide our subspecialty physician clients comprehensive diagnostics and timely, accurate reports enabling the best patient care. For more about the company, please visit http://www.CBLPath.com.

 

New CAP Case of the Month Available

January 2011
October Case Photo
VIEW CASE WITH
• MAC/PC Users: WebViewer
• PC users: ImageScope
(First time use - * Download software)
 

Case of the Month is a resource for pathologists to assess theirdiagnostic skills using digital whole slide imaging. Posted cases are selected from the CAP archives of the Performance Improvement Program in Surgical Pathology (PIP).

 

CLINICAL SUMMARY

Lymph Node

A 24-year-old woman was involved in a motor vehicle accident. Upon radiological work-up, a large incidental mass was identified in the anterior mediastinum. Excisional biopsy of a single enlarged lymph node was performed.

The master list with the correct answer

  1. Angiofollicular hyperplasia (Castleman disease)
  2. Follicular lymphoma
  3. Lymphocyte-predominant thymoma (WHO type B1)
  4. Plasmacytoma
  5. Reactive follicular hyperplasia
  6. Regressing follicular hyperplasia

View the appropriate diagnosis, critique and references

PREVIOUS CASE: PANCREAS
A 55-year-old woman underwent abdominal ultrasonography for evaluation of possible gallstones. Cholelithiasis could not be demonstrated, but there was a 7.5 cm multiloculated cyst involving the distal pancreas. Subsequent distal pancreatectomy revealed a multiloculated cyst (7.5 x 7.0 x 6.0 cm) filled with cloudy, amber-colored, thin fluid. The cyst wall ranged from 1mm to 3.0 mm in thickness. 
view case.

Go to CASE ARCHIVES

 Digital Pathology

Receive CAP Updates
CAP RSS Feed Subscribe to RSS

 

Definiens to host comprehensive digital pathology workshop at USCAP 2011

Join Definiens on March 1st at the 100th Annual USCAP meeting, for a seminar entitled, “Digital Pathology Image Analysis in Translational Research and Clinical Trials" with special guest speakers:

  • Mark Lloyd, Manager – Analytical Microscopy Core Facility – Moffitt Cancer Center;
  • Dr. Marilyn Bui, Scientific Director, Analytic Microscopy Core Facility and Director of Cytopathology Fellowship - Moffitt Cancer Center
  • Dr. Belinda Cancilla, Associate Director Pharmacology and Manager Histology Core – Exelixis

When: 5:30pm, March 1st
Where: San Antonio Marriott Rivercenter

First Talk:

Title: How to get the most out of digital pathology in translational research?

Presenters:

Mark Lloyd, Manager – Analytical Microscopy Core Facility – Moffitt Cancer Center;

Dr. Marilyn Bui, Scientific Director, Analytic Microscopy Core Facility and Director of Cytopathology Fellowship - Moffitt Cancer Center

Abstract:

Cancer cell heterogeneity has long been accepted to be a factor of cancer progression and resistance to therapeutic intervention. To gain quantitative insights in tumor heterogeneity, many studies have been carried out at the molecular and genetic scale; however, there is little information on tumor heterogeneity at the cellular scale by image analysis. While genetics and signaling networks are the basis of core traits; cell variability with respect to their ability to perform core trait functions under diverse conditions within the physical microenvironment (PME) is what may decide trends in tumor growth dynamics. This study investigates the utility of digital slide scanning in conjunction with image analysis algorithms to evaluate details of the interaction between breast cancer progressions as it relates to changes in the tumor’s physical microenvironment (PME).

Second Talk:

Title: Digital pathology and image analysis in clinical trials

Presenter:

Dr. Belinda Cancilla, Associate Director Pharmacology and Manager Histology Core – Exelixis

Digital pathology combined with advanced image analysis methods has enabled researchers to generate extensive data sets for a variety of samples types, in both histopathology applications as well as analysis of pharmacodynamic (PD) biomarkers in tumor and surrogate tissues. For histopathology, data generated by capturing whole slides at high magnification together with an automated image analysis approach will be compared to more traditional manual methods for histologically stained samples (hematoxylin and eosin in FFPE sections, and oil red O in frozen sections). For PD biomarkers, analysis of signaling pathway inhibition by examining phosphoprotein expression in immunofluorescently labeled samples will be discussed. Novel applications for 3D image analysis of PD biomarkers in surrogate tissues such as hair wholemount confocal images will also be presented.

Also, be sure to check out Definiens Tissue Studio at booth # 573.

FREE Special Lab Products Review: A Tale of Two Solutions Achieving Balance in Automation: Optimizing Time and Staff

FREE Special Lab Products Review
   

download your report now!

 

Download Your FREE Special Report Today!

 A Tale of Two Solutions Achieving Balance in Automation: Optimizing Time and Staff
Diagnostic laboratories continually seek to balance the physician’s request for faster test results with the productive capacity of the lab staff. This “need for speed” is complicated by increasing test volumes and a critical shortage of lab techs. One solution provided by the IVD industry is to improve laboratory productivity by providing mechanical automation.
The ability of equipment to increase lab work volumes is important to successful use of automation, but also important how equipment minimizes the time lab techs spend in loading, setup, and routine maintenance of equipment. To fully evaluate the productivity of lab automation systems, analysis must look at reductions in time needed for individual assays, throughput ability, and how the systems free up lab tech time for other tasks.
The Dark Report is happy to offer our readers a chance to download our recently published FREE Report “A Tale of Two Solutions Achieving Balance in Automation: Optimizing Time and Staff” at absolutely no charge. This free download will provide readers with a detailed overview of laboratory productivity and automation solutions.

---Here is just some of what you will take away...

 

  1. Successfully evaluate productivity in your lab
  2. Individual assay turnaround times (TAT)
  3. Testing throughput and labor efficiency
  4. For more about how to speed up your lab with higher volumes of testing, please CLICK HERE

download your report now!

 

Table of Contents

Disclosure — Page 2
Preface — Page 4
Chapter 1. Study Methodology — Page 6
Chapter 2. Protocol Results — Page 8
Chapter 3. Operational Efficiencies Page 11
Chapter 4. Conclusion — Page 14

Appendices
  
A-1 About Tim Baker — Page 17
A-2 About Jared Williams — Page 18
A-3 About Nexus Global Solutions — Page 19
A-4 About Karen Branz — Page 20
A-5 About DARK Daily — Page 21
A-6 About The Dark Intelligence Group, Inc., and THE DARK REPORT — Page 22
A-7 About the Executive War College on Laboratory and Pathology Management — Page 23

  
Terms of Use Page 28

download your report now!
  

FDA Approves First 3-D Scanning Device For Mammography

        The Wall Street Journal (2/12, Dooren) reported that the FDA on Friday announced it has approved a mammography device by Hologic Inc. The Selenia Dimensions System is the first device with the ability to generate three-dimensional images of the breast to be approved in the US. The agency expects that 3-D system will reduce the number of women who are called back for additional screening. Currently, about 10% of the women who receive mammograms are called back for additional testing because of unclear readings and false-positives in their original set of mammograms, according to FDA estimates.

539w         According to the Boston Globe (2/12, Weisman), the Selenia device is based "digital tomosynthesis, which can see through overlapping tissue often obscured in two-dimensional scans." The AP (2/14) adds that although the system "doubles the radiation exposure" for patients, the FDA emphasized that it also "increases" diagnosis accuracy. The agency approved the device based on "two studies" that demonstrated a "7-percent improvement in spotting cancerous tumors when viewing images from Hologic's device, compared with traditional 2-D images. ... 'Physicians can now access this unique and innovative 3-D technology that could significantly enhance diagnosis and treatment approaches,'" said FDA's Center for Devices and Radiological Health Director Jeffrey Shuren. The Selenia device is "already approved in Europe, Latin America and Asia."

        The Los Angeles Times (2/12, Zajac) noted that although the technology will "presumably reduce" the number of inconclusive initial mammograms, it is unclear whether the device would ultimately reduce the rate of breast cancer mortalities. Carol Lee, M.D., who chairs the American College of Radiology's Committee on Breast Imaging, "said it's too early to tell how useful the technology will be." It has not yet been shown whether 3-D scanning can pinpoint "more cancers," Dr. Lee said.

        Meanwhile, HealthDay (2/13) reports that currently, about "200,000 women" are diagnosed with breast cancer each year, and one in eight women "will face a diagnosis of breast cancer sometime during their lifetime," according to NCI data. Reuters(2/14, Heavey), CNN (2/11, Caruso) in its "The Chart" blog and MedPage Today (2/13) also reported FDA's approval of the 3-D scanning device.

 

GE Healthcare to Discuss Meaningful Use and Role of Accountable Care at HIMSS11

BARRINGTON, Ill., Feb 18, 2011 (BUSINESS WIRE) --

At HIMSS11, GE Healthcare's focus will be on helping organizations reduce the complexity of achieving Meaningful Use and going beyond certification to optimizing care delivery. With the experience of helping thousands of organizations address Stage 1, and the commitment to being prepared for future requirements for healthcare providers, GE Healthcare will be a reliable resource -- at every stage.

Visitors to the GE Healthcare booth (#2401) can learn how to:

Deliver quality outcomes and meet pay-for-performance requirements with the Centricity* portfolio of EMR solutions. Enhance care coordination and connect disparate healthcare systems across facilities via a robust Health Information Exchange platform. Leverage new innovations for healthcare delivery in the areas of digital pathology and clinical knowledge platforms, resulting from GE Healthcare's strategic partnerships with leading institutions such as UPMC, Intermountain Healthcare and Mayo Clinic. Speed patient care through the integration of tools, including patient monitors, wireless devices and workflows, and IT solutions to enhance clinical decision making.

GE Healthcare's exhibition will also feature an engaging series of live presentations on provider priorities from Accountable Care Organizations to Meaningful Use, as well as solution demonstrations.

"For us, HIMSS is a chance to engage with healthcare providers on issues that really matter," said Vishal Wanchoo, President and CEO of GE Healthcare IT. "They're bringing us the demands of their patients and we're responding through technology that reduces the cost while increasing the access to quality healthcare for all. This is an exciting time to be in this field. We look forward to showing you why."

*GE, the GE monogram, Centricity are registered trademarks of General Electric Company.

ABOUT GE HEALTHCARE:

GE Healthcare provides transformational medical technologies and services that are shaping a new age of patient care. Our broad expertise in medical imaging and information technologies, medical diagnostics, patient monitoring systems, drug discovery, biopharmaceutical manufacturing technologies, performance improvement and performance solutions services help our customers to deliver better care to more people around the world at a lower cost. In addition, we partner with healthcare leaders, striving to leverage the global policy change necessary to implement a successful shift to sustainable healthcare systems.

Our "healthymagination" vision for the future invites the world to join us on our journey as we continuously develop innovations focused on reducing costs, increasing access and improving quality around the world. Headquartered in the United Kingdom, GE Healthcare is a unit of General Electric Company (NYSE: GE | PowerRating). Worldwide, GE Healthcare employees are committed to serving healthcare professionals and their patients in more than 100 countries. For more information about GE Healthcare, visit our website at http://www.gehealthcare.com.

For our latest news, please visit http://newsroom.gehealthcare.com.

 

 

 

Can you share a few slides?

Pap slide submissions are needed for the CAP Interlaboratory Comparison Program in Gynecologic Cytology. All submitted slides are subject to rigorous review by three cytopathologists, and the College pays up to $20 per accepted slide.

Slides not accepted into the program can be returned if requested, and accepted slides can be tracked and returned should the need arise.

All submitted slides must meet these standards:

  • All LSIL, HSIL, and carcinoma cases must have tissue confirmation of the reference interpretation. Per CMS requirement, please write the biopsy diagnosis on the donor sheet or send an anonymized copy of the biopsy report.
  • Each submitted case should be accompanied by appropriate clinical information for the patient (for example, age, LMP, prior hysterectomy).
  • Materials submitted must be free of patient identifiers.
  • ThinPrep Imager slides should be stained specifically for use with ThinPrep Imager.

Not acceptable are broken, cracked, chipped, or repaired slides; slides with air bubbles or with plastic or liquid coverslips; slides showing fading, drying (particularly around the periphery), or intense orangeophilia; slides more than seven years old; and cases interpreted as moderate dysplasia, ASC-US, ASC-H, or AGC.

Contact Larry Flennoy (847-832-7275, lflenno@cap.org) for more information or to have a submission sheet and slide shipping materials mailed to you. Or, find submission sheets at http://www.cap.org, Cytopathology Topic Center page.

 

 

Check out Nikon’s One-Stop Solution for Gross Specimens

 If you are attending USCAP check this out and other Nikon products related to telepathology in Booth #348.

Mi

Introducing Nikon's one-stop solution for gross specimen imaging.

Nikon's Mi macro imaging station revolutionizes gross histology documentation by addressing the workflow necessary to cleanly and safely capture, annotate, compare, and measure images of biopsied gross specimens in the pathology, histology and forensic lab. The Mi offers a stable, versatile, contamination-free imaging station, providing the ideal first step in capturing an entire pathology case history.

 LED lighting - Provides bright, sharp images with perfect detail, and ensures that specimens will not be damaged by heat.

 Ease of Use - With its simple interface and straightforward operating actions, users need not have expertise in photography for successful imaging.

 Top Quality Camera - Nikon DS-Fi1 camera with motorized lens provides high resolution imaging and offers the option to select either standard or publication quality images, as required.

 Reduced Risk of Contamination - Workstation is water and splash-resistant, and user has option to carry out all functions via touch screen, keyboard, mouse, foot pedal or barcode reader.

 Pathology-Focused Software - Simple menu options enable rapid image capture and annotation, live comparison, object measurement and counting, and database functions to maximize information from images.

For a look at Mi-related product literature and multi-media resources, click here.

Data Sheet, Brochure, White Paper, Image Gallery, Demo

For even more information, contact us at nikoninstruments@nikon.net.

If you would like a price quote, click here.

 

Aperio Webinar: Adopting Digital Pathology for Core Labs – February 22

Tuesday, February 22, 2011

7:00am PST, 10:00am EST, 3:00pm GMT
 OR
4:00pm PST, 7:00pm EST
(8:00am Japan Standard Time / 9:00am Australia EST February 23) 
Presenters:
Charles R. Handorf, M.D., Ph.D.
Anand Kulkarni, M.D.
University of Tennessee Health Science Center

In this 60-minute, complimentary webinar, Drs. Handorf and Kulkarni will discuss adopting digital pathology for core labs.

Topics include:
Digital imaging: Service and support for core labs
Digital imaging integration for biobanks
Instrument procurement and operational costs
Future of digitized images
To register for the 7am PST session, click here.
https://aperio.webex.com/aperio/onstage/g.php?t=a&d=485058319

To register for the 4pm PST session, click here.
https://aperio.webex.com/aperio/onstage/g.php?t=a&d=485629421

You may also register by visiting the Aperio Events page.

You will receive a confirmation email upon registration with a web link that will lead you to the online event. Simply visit the link at the assigned time. The session is secure and easy to access. If you have any questions or would like additional information, please contact the Aperio Events Team at events@aperio.com or 760.539.1192.

FDA clears first app for image review on iPads, iPhones

Pathology Next? Pathology could use this as a leverage point to use pathology digital imaging on iPADs and other related media.

February 4, 2011 -- The U.S. Food and Drug Administration (FDA) has issued clearance of MIM Software Mobile MIM application, the first mobile image viewing application to receive clearance for diagnostic use on Apple's iPhone and iPad devices.

The clearance covers viewing and making medical diagnoses using iPads and iPhones for CT, MR, and nuclear medicine images (including PET), but the software is not intended to replace full workstations, and it's indicated for use only when there is no access to a workstation, according to the FDA.

While smartphones and tablets such as Apple's iPhone and iPad have drawn interest for their potential in radiology applications, broader clinical use has been held back due to an early 2010 FDA decision to classify Mobile MIM as a class III device requiring premarket approval (PMA) instead of a class II device requiring 510(k) clearance.

The situation changed in the summer of 2010, however, when MIM Software was discussing its appeal of the 510(k) decision with the FDA, said Mark Cain, chief technology officer of the Cleveland-based company.

"We were able to identify many of the key issues that concerned them [and] it was jointly decided that another 510(k) would be the best way to proceed," Cain said.

With the clearance of Mobile MIM, the regulatory picture has now brightened, likely ushering in increased investment in these applications.

In its evaluation of Mobile MIM, the FDA said it reviewed performance test results on various portable devices, measuring luminance, image quality (resolution), and noise in accordance with international standards and guidelines. The FDA also reviewed results from demonstration studies with qualified radiologists under different lighting conditions.

"All participants agreed that the device was sufficient for diagnostic image interpretation under the recommended lighting conditions," the FDA said in a statement.

With Mobile MIM, images are compressed for secure network transfer and sent to the appropriate portable wireless device. Mobile MIM also enables physicians to measure distances and image intensity values, as well as display measurement lines, annotations, and regions of interest, the FDA said.

The FDA noted that there can be significant variations in the display performance of mobile devices, even between mobile devices of the same model. However, the Mobile MIM application includes sufficient labeling and safety features to mitigate the risk of poor image display due to improper screen luminance or lighting conditions, according to the FDA.

"The device includes an interactive contrast test in which a small part of the screen is a slightly different shade than the rest of the screen," the FDA said in a statement. "If the physician can identify and tap this portion of the screen, then the lighting conditions are not interfering with the physician's ability to discern subtle differences in contrast. In addition, a safety guide is included within the application."

MIM Software welcomes the clearance, particularly because the FDA had turned down the company's original 510(k) application

"After three years, it is a relief to see this chapter close," Cain said. "We're looking forward to the next step."

By Erik L. Ridley
AuntMinnie.com staff writer
February 4, 2011

Copyright (c) 2011 AuntMinnie.com